Hualan Biological EngineeringInc

SHE:002007 China Biotechnology
Market Cap
$3.79 Billion
CN¥27.83 Billion CNY
Market Cap Rank
#4969 Global
#583 in China
Share Price
CN¥15.23
Change (1 day)
-0.52%
52-Week Range
CN¥14.98 - CN¥17.72
All Time High
CN¥235131.81
Categories
Companies in China Biotechnology
About

Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more

Hualan Biological EngineeringInc (002007) - Net Assets

Latest net assets as of September 2025: CN¥13.25 Billion CNY

Based on the latest financial reports, Hualan Biological EngineeringInc (002007) has net assets worth CN¥13.25 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥16.27 Billion) and total liabilities (CN¥3.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥13.25 Billion
% of Total Assets 81.45%
Annual Growth Rate 26.25%
5-Year Change 70.94%
10-Year Change 256.47%
Growth Volatility 56.73

Hualan Biological EngineeringInc - Net Assets Trend (2001–2024)

This chart illustrates how Hualan Biological EngineeringInc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hualan Biological EngineeringInc (2001–2024)

The table below shows the annual net assets of Hualan Biological EngineeringInc from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥13.85 Billion +3.17%
2023-12-31 CN¥13.42 Billion +9.91%
2022-12-31 CN¥12.21 Billion +34.71%
2021-12-31 CN¥9.06 Billion +11.90%
2020-12-31 CN¥8.10 Billion +17.67%
2019-12-31 CN¥6.88 Billion +19.25%
2018-12-31 CN¥5.77 Billion +19.22%
2017-12-31 CN¥4.84 Billion +9.17%
2016-12-31 CN¥4.44 Billion +14.19%
2015-12-31 CN¥3.88 Billion +6.83%
2014-12-31 CN¥3.64 Billion +9.82%
2013-12-31 CN¥3.31 Billion +16.95%
2012-12-31 CN¥2.83 Billion +9.68%
2011-12-31 CN¥2.58 Billion +7.28%
2010-12-31 CN¥2.41 Billion +29.62%
2009-12-31 CN¥1.86 Billion +62.22%
2008-12-31 CN¥1.14 Billion +70.84%
2007-12-31 CN¥669.71 Million +13.84%
2006-12-31 CN¥588.30 Million +6.81%
2005-12-31 CN¥550.80 Million +10.05%
2004-12-31 CN¥500.48 Million +285.77%
2003-12-31 CN¥129.74 Million +37.88%
2002-12-31 CN¥94.10 Million +44.71%
2001-12-31 CN¥65.02 Million --

Equity Component Analysis

This analysis shows how different components contribute to Hualan Biological EngineeringInc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 52019.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥7.73 Billion 65.23%
Common Stock CN¥1.83 Billion 15.42%
Other Components CN¥2.30 Billion 19.35%
Total Equity CN¥11.86 Billion 100.00%

Hualan Biological EngineeringInc Competitors by Market Cap

The table below lists competitors of Hualan Biological EngineeringInc ranked by their market capitalization.

Company Market Cap
Beijing Jetsen Tech Co
SHE:300182
 		$2.00 Billion
Green Brick Partners Inc
NYSE:GRBK
 		$2.00 Billion
Godrej Properties Limited
NSE:GODREJPROP
 		$2.00 Billion
Iwatani Corporation
MU:IWA
 		$2.00 Billion
CECEP Wind-Power Corp Co Ltd
SHG:601016
 		$2.00 Billion
VERRA MOBILITY A DL-0001
F:0YK
 		$2.00 Billion
Budimex S.A.
WAR:BDX
 		$2.00 Billion
AmTrust Financial Services Prf 7 25 Exp15Jun2055
PINK:AFFS
 		$2.00 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hualan Biological EngineeringInc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 11,359,430,727 to 11,858,784,465, a change of 499,353,738 (4.4%).
  • Net income of 1,087,850,986 contributed positively to equity growth.
  • Dividend payments of 467,829,671 reduced retained earnings.
  • Share repurchases of 106,786,852 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.09 Billion +9.17%
Dividends Paid CN¥467.83 Million -3.95%
Share Repurchases CN¥106.79 Million -0.9%
Other Changes CN¥-13.88 Million -0.12%
Total Change CN¥- 4.40%

Book Value vs Market Value Analysis

This analysis compares Hualan Biological EngineeringInc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.35x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 427.51x to 2.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.04 CN¥15.23 x
2002-12-31 CN¥0.05 CN¥15.23 x
2003-12-31 CN¥0.07 CN¥15.23 x
2004-12-31 CN¥0.29 CN¥15.23 x
2005-12-31 CN¥0.30 CN¥15.23 x
2006-12-31 CN¥0.32 CN¥15.23 x
2007-12-31 CN¥0.37 CN¥15.23 x
2008-12-31 CN¥0.63 CN¥15.23 x
2009-12-31 CN¥0.93 CN¥15.23 x
2010-12-31 CN¥1.21 CN¥15.23 x
2011-12-31 CN¥1.32 CN¥15.23 x
2012-12-31 CN¥1.45 CN¥15.23 x
2013-12-31 CN¥1.71 CN¥15.23 x
2014-12-31 CN¥1.88 CN¥15.23 x
2015-12-31 CN¥2.02 CN¥15.23 x
2016-12-31 CN¥2.33 CN¥15.23 x
2017-12-31 CN¥2.57 CN¥15.23 x
2018-12-31 CN¥3.05 CN¥15.23 x
2019-12-31 CN¥3.60 CN¥15.23 x
2020-12-31 CN¥4.14 CN¥15.23 x
2021-12-31 CN¥4.55 CN¥15.23 x
2022-12-31 CN¥5.70 CN¥15.23 x
2023-12-31 CN¥6.23 CN¥15.23 x
2024-12-31 CN¥6.49 CN¥15.23 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hualan Biological EngineeringInc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 9.17%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 24.84%
  • • Asset Turnover: 0.27x
  • • Equity Multiplier: 1.38x
  • Recent ROE (9.17%) is below the historical average (18.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 23.76% 12.42% 0.64x 3.00x CN¥8.95 Million
2002 30.66% 16.71% 0.71x 2.57x CN¥19.44 Million
2003 27.36% 14.03% 0.73x 2.69x CN¥22.52 Million
2004 8.26% 12.89% 0.50x 1.29x CN¥-8.69 Million
2005 9.98% 14.54% 0.52x 1.33x CN¥-79.72K
2006 14.23% 22.38% 0.43x 1.47x CN¥23.49 Million
2007 18.82% 34.30% 0.37x 1.50x CN¥56.43 Million
2008 17.00% 39.41% 0.38x 1.15x CN¥77.12 Million
2009 36.55% 49.85% 0.61x 1.21x CN¥441.99 Million
2010 28.23% 48.54% 0.49x 1.19x CN¥395.44 Million
2011 15.66% 39.20% 0.35x 1.16x CN¥134.01 Million
2012 11.54% 30.83% 0.33x 1.14x CN¥40.02 Million
2013 15.45% 42.53% 0.31x 1.18x CN¥167.60 Million
2014 15.82% 43.30% 0.33x 1.11x CN¥198.18 Million
2015 16.11% 40.03% 0.37x 1.10x CN¥223.32 Million
2016 18.50% 40.33% 0.42x 1.10x CN¥358.52 Million
2017 17.59% 34.66% 0.45x 1.12x CN¥354.15 Million
2018 20.62% 35.42% 0.50x 1.17x CN¥586.79 Million
2019 19.62% 34.69% 0.49x 1.16x CN¥629.14 Million
2020 21.43% 32.11% 0.50x 1.33x CN¥860.25 Million
2021 15.58% 29.28% 0.38x 1.38x CN¥465.20 Million
2022 10.35% 23.83% 0.31x 1.42x CN¥36.41 Million
2023 13.04% 27.74% 0.33x 1.42x CN¥345.64 Million
2024 9.17% 24.84% 0.27x 1.38x CN¥-98.03 Million

Industry Comparison

This section compares Hualan Biological EngineeringInc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $953,005,438
  • Average return on equity (ROE) among peers: 12.14%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hualan Biological EngineeringInc (002007) CN¥13.25 Billion 23.76% 0.23x $2.00 Billion
Shenzhen CAU Technology Co Ltd (000004) $124.02 Million 4.50% 1.13x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $525.49 Million 14.76% 1.41x $1.02 Billion
Nanhua Bio Medicine Co Ltd (000504) $174.34 Million 36.11% 1.61x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $244.62 Million
Chengzhi Shareholding Co Ltd (000990) $1.69 Billion 3.06% 0.97x $850.04 Million
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.09 Billion 4.42% 0.71x $784.18 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $831.21 Million 22.32% 0.12x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $2.04 Billion 5.44% 0.31x $398.99 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $456.61 Million 23.20% 0.29x $347.95 Million